Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), has been selected by sanofi pasteur, the vaccines division of the sanofi-aventis Group, as its Preferred Provider of Randomization and Trial Supply Management RTSM technologies. Through this relationship, Perceptive is helping sanofi pasteur to achieve more efficient data collection, faster patient enrollment and more streamlined trial supply management for increasingly complex vaccine trials.
"Perceptive is pleased to provide sanofi pasteur with our dedicated expertise and innovation, represented through leading RTSM technologies, to help improve efficiencies of their clinical development programs," said Steve Kent, President, Perceptive Informatics. "Our relationship with sanofi pasteur is representative of the commitment we have to helping our key customers gain greater visibility into their trials and improve data access for faster, better decision making."
Perceptive's RTSM solution randomizes a higher volume of patients in a shorter period of time, processes investigator inquiries faster, and gains more trial supply efficiencies. "Perceptive looks forward to continuing to work with sanofi pasteur to provider greater cost savings, more robust inventory control, and better optimized supply chain processes," said Mr. Kent.
Perceptive's ClinPhone® RTSM technologies for the biopharmaceutical industry offer validated randomization methods, automated inventory control, dispensing and titration management, emergency code break capabilities, and real-time supply reporting. The solutions provide sophisticated reporting to monitor trial management performance, nding and forecasting information, and in-depth data analysis. The ClinPhone RTSM technologies can support clinical trials worldwide that include multiple languages and require real-time, web-based data collection. The solutions, which enable Internet and telephone access for end-users to perform study activities via one or both interfaces, provide secure access, a detailed audit trail, transaction logging, and compliance with FDA 21 CFR Part 11.
For more information about the ClinPhone RTSM technologies from Perceptive Informatics, visit www.perceptive.com/ClinPhone-RTSM.
About Perceptive Informatics
Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. The Perceptive Informatics industry-leading eClinical product portfolio is built on advanced technology that benefits from extensive medical and clinical expertise as well as a deep understanding of the regulatory environment. The portfolio includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). For more information about the integrated solutions in Perceptive’s eClinical Suite visit: www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 54 countries around the world, and has approximately 9,500 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $24 million over the second, third, and fourth quarters of Fiscal Year 2010; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2010 as filed with the SEC on May 7, 2010 which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.